Latest News

February 13, 2026

The Winter 2026 advocacy blog Considering Clinical Trials is now available

February 9, 2026

Natasha Edwin, MD, community co-chair of the ECOG-ACRIN Myeloma Committee, highlights why patients in rural areas need access to quality clinical trials

February 3, 2026

ECOG-ACRIN legacy lung cancer studies E1594 and E5508 cited in ASCO Living Guideline 2026.3.0, therapy for stage 4 NSCLC without driver alterations

January 31, 2026

The January 2026 News from ECOG-ACRIN blog is now available

January 29, 2026

Press Release: New England Journal of Medicine publishes phase 3 PATINA (PrECOG PrE0111) trial data demonstrating a significant progression-free survival benefit with palbociclib in metastatic HR+, HER2+ breast cancer

January 21, 2026

ECOG-ACRIN study identifies high rates of vulnerability in AML patients aged 60 years or older

January 8, 2026

WATCH: Drs. Jen Specht and Heather Racine discuss the FEATURE (EA1183) trial results…a game-changer for bone-dominant metastatic breast cancer

January 8, 2026

AI models advance individualized breast cancer recurrence risk assessments

January 8, 2026

Caris, cooperative groups advancing AI models that can improve breast cancer risk assessments (access requires free registration)


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
37

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group